Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diazoxide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ11 known ✓ | Q14654 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | LTK | P29376 | 1/20 | 0.51 |
| ▸ | GRK5 | P34947 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | PRKX | P51817 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.51 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.51 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazoxide SCHEMBL29384603 | 1.00 | CHEK1 (0.51) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL1725216 | 0.98 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL1725516 | 0.98 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL1726275 | 0.98 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL28482607 | 0.94 | CHEK1 (0.46) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL10521551 | 0.87 | CHEK1 (0.51) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL225394 | 0.85 | CHEK1 (0.40) | CHEK1DAPK3MAP4K4RETPIM1 | |
| Diazoxide SCHEMBL3920344 | 0.85 | CHEK1 (0.40) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL12570063 | 0.83 | CA2 (0.47) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL11694453 | 0.83 | CHEK1 (0.50) | CHEK1DAPK3MAP4K4RETPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15238 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070304-A | High concentration formulations for anti-insulin receptor antibodies and uses thereof | 瑞泽乐特公司 | 2026-05-19 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4434588-B1 | AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-12589098-B2 | Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a KATP channel opener | SEDOGEN LLC (US) | 2026-03-31 | — | — | US | claimed |
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20260070996-A1 | FORMULATIONS FOR ANTI-INSULIN RECEPTOR ANTIBODY AND USES THEREOF | REZOLUTE INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260070972-A1 | MODULATORS | XOMA US LLC (US) | 2026-03-12 | — | — | US | claimed |
| US-4396616-A | DIURETICS, ENZYME INHIBITORS | MERCK & CO., INC. (US) | 1983-08-02 | — | — | US | claimed |
| EP-0083923-A2 | Aminoacyl-containing dipeptide derivatives useful as antihypertensives | MERCK & CO. INC. (US) | 1983-07-20 | — | — | EP | claimed |
| EP-0081094-A1 | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents | MERCK & CO. INC. (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0079522-A1 | N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
| EP-0061187-A1 | Bicyclic lactams as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
| EP-0049842-A2 | Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-21 | — | — | EP | claimed |
| EP-0049505-A2 | Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | claimed |
| EP-0046289-A2 | Substituted enantholactam derivatives as antihypertensives, a process for preparing and a pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |
| EP-0046291-A2 | Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates | MERCK & CO. INC. (US) | 1982-02-24 | — | — | EP | claimed |